Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years-Reference-Cited by-同舟云学术

Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years

Published:2022-04-21 Issue:8 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Estepp Jeremie H.¹,Kalpatthi Ram²,Woods Gerald³,Trompeter Sara⁴,Liem Robert I.⁵^ORCID,Sims Kacie⁶,Inati Adlette⁷,Inusa Baba P. D.⁸^ORCID,Campbell Andrew⁹^ORCID,Piccone Connie¹⁰,Abboud Miguel R.¹¹,Smith‐Whitley Kim¹²,Dixon Sandra¹³,Tonda Margaret¹³,Washington Carla¹³,Griffin Noelle M.¹³,Brown Clark¹⁴

Affiliation:

1. St. Jude Children's Research Hospital Memphis Tennessee USA

2. UPMC Children's Hospital of Pittsburgh Pittsburgh Pennsylvania USA

3. Children's Mercy Hospital Kansas City Missouri USA

4. University College London Hospitals NHS Foundation Trust London UK

5. Ann and Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA

6. St. Jude Affiliate Clinic Baton Rouge Baton Rouge Los Angeles USA

7. School of Medicine, Byblos and Nini Hospital Lebanese American University Tripoli Lebanon

8. Guy's and Saint Thomas' NHS Foundation Trust London UK

9. Division of Hematology Children's National Hospital Washington District of Columbia USA

10. Department of Pediatric Hematology Carle Foundation Hospital Urbana Illinois USA

11. American University of Beirut Medical Center Beirut Lebanon